Skip to main content
Premium Trial:

Request an Annual Quote

Thermo Fisher Completes Finnzymes Acquisition

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Thermo Fisher Scientific today said that it has completed its acquisition of Finnzymes for an undisclosed sum.

Espoo, Finland-based Finnzymes makes reagents, consumables, kits, and instruments for molecular biology applications. Its proprietary DNA polymerases, called Phire and Phusion, and high-speed miniaturized thermal cyclers will expand Thermo Fisher's portfolio of reagents and other consumables for the molecular biology research and diagnostics markets.

Thermo announced the deal to acquire Finnzymes early last month. The acquired firm had full-year 2009 revenues of $20 million and will be integrated into Thermo Fisher's Analytical Technologies segment.

The Scan

Should've Been Spotted Sooner

Scientists tell the Guardian that SARS-CoV-2 testing issues at a UK lab should have been noticed earlier.

For Martian Fuel

Researchers have outlined a plan to produce rocket fuel on Mars that uses a combination of sunlight, carbon dioxide, frozen water, cyanobacteria, and engineered E. coli, according to Gizmodo.

To Boost Rapid Testing

The Washington Post writes that new US programs aim to boost the availability of rapid at-home SARS-CoV-2 tests.

PNAS Papers on Strawberry Evolution, Cell Cycle Regulators, False-Positive Triplex Gene Editing

In PNAS this week: strawberry pan-genome, cell cycle-related roles for MDM2 and MDMX, and more.